GEA

EQS-News: GEA’s factory in Elsdorf sets new standards in pharmaceutical production

Retrieved on: 
Wednesday, April 10, 2024
Electricity, EUR, Biodiversity, Growth, Disease, GEA, Food, Immunization, Fruit, Vaccine, Workplace

Groundbreaking ceremony for GEA’s second “Factory of the Future” covering an area of over 40,000 m2 in Elsdorf, Germany

Key Points: 
  • Groundbreaking ceremony for GEA’s second “Factory of the Future” covering an area of over 40,000 m2 in Elsdorf, Germany
    Düsseldorf, March 22, 2024 – Construction of GEA’s new pharmaceutical technology center in Elsdorf, Germany, begins today – setting new industry benchmarks.
  • With people increasingly aware of the major role immunization plays in preventing disease, the market for vaccines is growing rapidly worldwide.
  • At Elsdorf, state-of-the-art processes and working methods as well as the associated digitalization are the main focus alongside sustainable construction.
  • This is why the new pharmaceutical technology center is going to be built according to the highest sustainability standards.

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

Retrieved on: 
Tuesday, March 12, 2024
GEA, Patient, Breast cancer, Interest, Jazz Pharmaceuticals, Cancer, BTC, Cholangiocarcinoma

DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m.

Key Points: 
  • DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m.
  • ET, focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers.
  • Interested parties may register for the zanidatamab R&D Day webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations .
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

Retrieved on: 
Tuesday, March 12, 2024
GEA, Patient, Breast cancer, Interest, Jazz Pharmaceuticals, Cancer, BTC, Cholangiocarcinoma

DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m.

Key Points: 
  • DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m.
  • ET, focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers.
  • Interested parties may register for the zanidatamab R&D Day webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations .
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

EQS-News: GEA sees earnings rise again in fiscal year 2023 and proposes dividend increase

Retrieved on: 
Wednesday, March 13, 2024
Annual general meeting, ROCE, Share repurchase, Supervisory board, GEA, Climate, Food, Growth, Treasury, Climate change, Health care, EUR, DAX, Organic, Policy, Annual, Environment, Renewable energy

Group revenue rose by 8.4 percent organically and by 4.0 percent on a reported basis to EUR 5,373 million.

Key Points: 
  • Group revenue rose by 8.4 percent organically and by 4.0 percent on a reported basis to EUR 5,373 million.
  • “In the face of the numerous challenges in fiscal year 2023, we managed to further improve our key financial figures.
  • EBITDA before restructuring expenses rose by EUR 62 million, or 8.7 percent, to EUR 774.3 million (2022: EUR 712.0 million).
  • Group profit for fiscal year 2023 came to EUR 392.8 million (2022: EUR 401.4 million).

EQS-News: Klöckner & Co becomes GEA’s first supplier of CO₂-reduced stainless steel

Retrieved on: 
Wednesday, March 13, 2024
Carbon, GEA, Stainless steel, Transport, NRW, CO2

Delivery of first batches of CO2-reduced stainless steel to the GEA production site in Bönen (North Rhine-Westphalia, Germany)

Key Points: 
  • Delivery of first batches of CO2-reduced stainless steel to the GEA production site in Bönen (North Rhine-Westphalia, Germany)
    The carbon footprint of the stainless steel is around 90% lower than conventional material; the product corresponds to the “Pro” category in the Nexigen® categorization for “green” stainless steel developed by Klöckner & Co
    Duisburg, Germany, February 27, 2024 – Klöckner & Co will be the first supplier of CO2-reduced stainless steel for the technology group GEA.
  • The coil will be delivered to the GEA production site in Bönen (NRW) via Klöckner & Co’s German subsidiary Becker Stainless.
  • The coil of the Klöckner brand Nexigen® for CO2-reduced products and services has a carbon footprint that is around 90% lower than that of conventional stainless steel.
  • This places it in the “Pro” category of Klöckner & Co’s specifically developed Nexigen® product categorization for CO2-reduced stainless steel.

Sunrun Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 21, 2024
Acquisition, LMI, Revenue stream, Solar energy, Contraction, GEA, Absorption, Vivint Solar, Growth, Solar System, Customer, ITC, CO2, Renewal, Economics, Asset, Renewable energy

Customers grew 17% in the fourth quarter of 2023 compared to the fourth quarter of 2022.

Key Points: 
  • Customers grew 17% in the fourth quarter of 2023 compared to the fourth quarter of 2022.
  • Subscriber Value was $50,302 in the fourth quarter of 2023, an 18% increase compared to the fourth quarter of 2022.
  • Total revenue was $516.6 million in the fourth quarter of 2023, down $92.6 million, or 15%, from the fourth quarter of 2022.
  • During the fourth quarter of 2023, Sunrun recorded a $58.7 million non-cash charge related to its investment in Lunar Energy.

EQS-News: GEA invests EUR 18 million in technology center for alternative proteins in the USA

Retrieved on: 
Wednesday, February 14, 2024
Filtration, Fermentation, Senior, Biotechnology, USD, Ethics, GEA, Investment, FDA, Food, Seafood, Meat, Climate change, EUR, Bioreactor, Protein, ATC, Food security, Sterilization, Fine chemical

GEA is to establish EUR 18 million technology center for sustainable alternatives to meat, dairy, seafood and egg in the USA

Key Points: 
  • GEA is to establish EUR 18 million technology center for sustainable alternatives to meat, dairy, seafood and egg in the USA
    Significant demand for technology in the fast-growing U.S. new food market
    Düsseldorf, Germany, February 14, 2024 – GEA is investing EUR 18 million (USD 20 million) in a technology center for alternative proteins in in the state of Wisconsin, USA.
  • Groundbreaking at the new GEA campus in Janesville is scheduled for spring of 2024, with the opening to follow one year later.
  • Prior to this, GEA inaugurated its technology center focusing on cell cultivation and fermentation in Hildesheim, Germany, in June 2023.
  • GEA’s new food technology center in Janesville, Wisconsin, USA, will be home to an end-to-end process line.

Advances Made in Grant to Improve Immunotherapy in Gastroesophageal Cancer

Retrieved on: 
Wednesday, February 7, 2024
Antigen, Massachusetts General Hospital, Immunotherapy, Research, GEA, Stomach cancer, Patient, Safety, Bone marrow, Dana–Farber Cancer Institute, DRS, Cancer, Doctor of Philosophy, De Gregorio, GEMINI, Pharmaceutical industry

They are making strides in their objective of improving immunotherapy in gastroesophageal cancer by identifying and characterizing additional target antigens for next-generation cellular therapies.

Key Points: 
  • They are making strides in their objective of improving immunotherapy in gastroesophageal cancer by identifying and characterizing additional target antigens for next-generation cellular therapies.
  • One immunotherapy that has shown very positive results in blood cancers is Chimeric Antigen Receptor (CAR) T cell therapy.
  • "We are indeed proud to play a part in the development of the next-generation cellular therapy for gastroesophageal cancer by Drs.
  • Dana-Farber Cancer Institute provides expert cancer care while advancing the understanding of cancer and related diseases.

Gender and the ethics of artificial intelligence: the subject of debate at the 3rd edition of LIDEResA

Retrieved on: 
Tuesday, February 6, 2024
Intelligence, Artificial Intelligence Center, GEA, Language, Hotel, Applied ethics, Amazon, Digital, Artificial intelligence, Spanish National Research Council, Communication, Microsoft, CSIC, Director general, Software development, Algorithm

The III Edition will take place on 15 February from 17:30 to 21:00 at the Hotel Índigo-Gran Vía in Madrid.

Key Points: 
  • The III Edition will take place on 15 February from 17:30 to 21:00 at the Hotel Índigo-Gran Vía in Madrid.
  • This question will be answered by experts in a technology that, as they will explain, is essential for the business environment and for the development of society.
  • The theme of the debate chosen for the occasion is "Gender, ethics and new technologies.
  • There is no point in advancing in technology if it perpetuates inequalities because it does not contain a gender focus to prevent it.

EQS-News: GEA achieves key milestone: Science Based Targets initiative (SBTi) validates 2040 net-zero target

Retrieved on: 
Tuesday, January 30, 2024
Science Based Targets initiative, Carbon accounting, GEA, DAX, Climate, Investment, Science, GHG, Geography, Renewable energy

Duesseldorf (Germany), January 25, 2024 – The Science Based Targets initiative has validated GEA’s 2040 net-zero target.

Key Points: 
  • Duesseldorf (Germany), January 25, 2024 – The Science Based Targets initiative has validated GEA’s 2040 net-zero target.
  • This is based on a scientifically validated assessment of the climate targets and the associated reduction measures.
  • The SBTi validation confirms that GEA’s pathway to net zero is consistent with the Paris Climate Agreement.
  • “To achieve our climate targets, we have drawn up a comprehensive Climate Transition Plan 2040.